 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Vakzine Projekt Management |
| Street 1: | Mellendorferstr. 9 |
| Street 2: | |
| City: | Hannover |
| Province: | |
| Post Code: | 30625 |
| Country: | Germany |
| Phone: | 495111699080 |
| Email: | info@vakzine-manager.de |
| Web Site: | http://www.vakzine-manager.de |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Is your organization legally registered in your country: | No |
| Organization Reach: | International |
| Organization Description: | |
| VPM is a private vaccine and drug development company with a product portfolio that targets a market of more than €6 billion (USD 7.1 billion). VPM develops products for the treatment of prostate cancer and multiple sclerosis as well as for the prevention of various infectious diseases. VPM was founded in 2002 and is based in Hannover, Germany. The company is seeking industry and financial partners to accelerate product development. Multiple Sclerosis Soluferon®, a second generation ß-interferon with increased bioavailability is in preclinical development for treatment of multiple sclerosis Tuberculosis VPM1002 is a live recombinant vaccine against tuberculosis. It is currently in phase II clinical trial in South Africa. Human Cytomegalo Virus Preventive vaccine against human cytomegalo virus in preclinical development |
|
| Total number of staff in your organization: | 6 - 10 |
| Number of full-time staff who are directly involved with TB: | 1 - 5 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 100 + |
| What is your organization's annual budget (USD) dedicated to TB? | Unable to disclose amount |
| How did you hear about the Stop TB Partnership: | Attendance at a TB related event |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| VPM develops a BCG replacement vaccine. | |
Geographical Reach | |
| Which country is your headquarters located in: | Germany |
| Which WHO region is the main focus of your work: | Global |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Germany India South Africa |
Specializations | |
|
Research and Development |
Specializations in Countries | |
| Research and Development | Germany |
| Research and Development | India |
| Research and Development | South Africa |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
New TB Vaccines: VPM develops a new recombiant TB vaccine. A prime vaccine to replace BCG. |
|
Declaration | |
| Declaration of interests: VPM is a private vaccine and drug development company with a product portfolio. VPM develops products for the treatment of prostate cancer and multiple sclerosis as well as for the prevention of TB and HCMV. VPM was founded in 2002 and is based in Hannover, Germany. The company is seeking industry and financial partners to accelerate product development. Prostate Cancer A clinical phase I/II trial has successfully been completed with an allogeneic prostate cancer vaccine Multiple Sclerosis Soluferon®, a second generation ß-interferon with increased bioavailability is in preclinical development for treatment of multiple sclerosis Tuberculosis VPM1002 is a live recombinant vaccine against tuberculosis. It is currently in phase II clinical trial. Human Cytomegalo Virus Preventive vaccine against human cytomegalo virus in preclinical development | |
| Application date: | |
| Last updated: | May 10, 2012 |